Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$767K Hold
9,800
﹤0.01% 3932
2026
Q1
$633K Buy
+9,800
New +$691K ﹤0.01% 3723
2018
Q2
Sell
-15,000
Closed -$294K 3764
2018
Q1
$294K Sell
15,000
-75,000
-83% -$1.45M ﹤0.01% 3161
2017
Q4
$1.82M Buy
+90,000
New +$1.65M ﹤0.01% 2199

Other funds holding HALO

David Shaw's HALO Position: Q2 2026 in Review

David Shaw increased its Halozyme (HALO) stake by 7.4% in Q2 2026, buying an estimated $9.39M and bringing the position to 2,006,479 shares worth $157M. The position accounts for 0.07% of the portfolio, ranked #278.

David Shaw first reported a position in HALO in Q1 2014 and has held it in 47 quarters since. The position peaked at $194M in Q3 2025. 665 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • David Shaw held 2,006,479 shares of Halozyme worth $157M as of Q2 2026.
  • David Shaw bought 137,771 Halozyme shares in Q2 2026, an estimated $9.39M.
  • Halozyme made up 0.07% of David Shaw's portfolio in Q2 2026, its #278 holding.
  • David Shaw first reported a position in Halozyme in Q1 2014 and has held it in 47 quarters since.
  • David Shaw's Halozyme position peaked at $194M in Q3 2025.
  • 665 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.